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Available online 4 December 2018Background: Carriage of carbapenem-resistant Enterobacteriaceae (CRE) in humans may contribute to the dis-
semination of CRE and impact on communities and healthcare facilities. Carbapenem-resistant Escherichia coli
(CREC) is one of themajor type of CRE in the human gut. Here, we describe a cross-sectional study to investigate
the prevalence of CREC, and in particular themcr-1 carrying CREC, in health volunteers in China.
Methods: During September to December 2016, 3859 non-duplicated stool specimens were collected from
healthy volunteers who received regular physical examinees in healthcare centers located in 19 provinces across
China. Enrichment culture supplemented meropenem was used to isolate CREC. Carbapenemase producing de-
terminants and themcr-1 genewere determined by PCR ampliﬁcation and sequencing. Isolates were further an-
alyzed by antibiotic susceptibility test, genotyping, and whole genome analysis.
Findings: A total of 92 non-duplicated CREC were isolated from 3859 stool specimens, among which 43 CREC are
carbapenemase positive. In addition, the co-existence of blaNDM and mcr-1 was found in 14 CREC, which also
showed resistance to themajority of all antimicrobial agents analyzed. The genetic backgroundof these CREC iso-
lates are highly diversiﬁed based on molecular typing. Furthermore, whole genome sequence indicated that
NDM-5 is the predominant determinant conferring carbapenem resistance in CREC, and that NDM-5 carrying
plasmids (IncX3) are very similar.
Interpretation: The incidence of CREC carriage in healthy people in Chinawas small; however, the co-existence of
CREC with mcr-1 is disconcerting. Therefore, pre-screening prior to admission and monitoring of patients on
high-dependency wards is highly recommended to control and prevent the dissemination of CRE in hospitals.
Outstanding Question: The high prevalence of CREC in the healthy people should not be underestimated, as itmay
increase the risk of infection. This knowledge could have impact on the pre-screening andmonitoring of CRE be-
fore patient administration.shaolinwang@ca
en access articl© 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Antimicrobial resistance has become a global concern that threatens
our ability to treat common infections caused by bacterial organisms.
Among the major multidrug-resistant organisms, the emergence andu.edu.cn
e under the CC BY-NCdissemination of carbapenem-resistant Enterobacteriaceae (CRE) is rec-
ognized as one of the most serious threats to public health worldwide
[1–6]. Infections caused by CRE are often associatedwith highmortality,
primarily due to the limited availability of therapeutic options [7,8]. The
recent increase in CRE were mainly due to the acquisition of carba-
penem hydrolyzing enzymes such as Klebsiella pneumoniae
carbapenemase (KPC) and the New Delhi metallo-β-lactamase (NDM)
[9,10]. The carbapenem resistance in K. pneumoniae is commonlymedi-
ated by blaKPC, often observed in the hospitalized patients, while that in
E. coliwas predominantly cause by blaNDM,which identiﬁed in both hos-
pitalized patients and healthy people.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Carbapenems Resistant Enterobacteriaceae (CRE) has become a
global threat to public health, and numerous studies have indi-
cated the wide prevalence of CRE in the hospital high-
dependency units. However, the carriage of CRE, especially indi-
viduals admitted to and subsequently discharged from hospitals,
has been underestimated and poorly studied.
Added value of this study
In this study, for the first time, a large scale observation study has
been conducted to determine the carriage of CRE in healthy volun-
teers in China, and the results indicated a 2.38% (95% CI,
1.95%-2.91%) national-wide carriage of CRE in the healthy peo-
ple. It is surprisingly that NDM-5 is the dominant determinants in
the CRE isolates. This study provides the first insight of the car-
riage of CRE in a large cohort of healthy people.
Implications of all the available evidence
The outcome of this study suggest that the surveillance and mon-
itoring of the carriage of CRE in the healthy people should be fur-
ther evaluated, particularly for patients admitted to hospital high-
dependency wards (e.g. oncology, ICU) to prevent nosocomial
outbreaks.
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ery of NDM-1 in India [11]. The rapid plasticity of blaNDM in such a short
period of time may enhance its growing importance not only in the
human but also in the food animals. These NDMvariants are highly sim-
ilar with only several amino acids difference. Their hydrolysis activity
toward carbapenem also varies. NDM-5 (Val88Leu, Met154Leu) and
its closely related variants, NDM-17 (Val88Leu, Met154Leu, Glu170Lys)
and NDM-20 (Val88Leu, Met154Leu, Arg270His), possess stronger
carbapenemase activity comparing with NDM-1, and the plasmids car-
rying NDM-5, NDM-17, or NDM-20 share signiﬁcant high identity over
99% [11]. In China, NDM-5 has been frequently observed during surveil-
lance of both clinical and food animal sectors [12–14].
Colistin is considered as the last resort treatment for life-threatening
infections caused by CRE. The recent emergence of the plasmid-
mediated genemcr-1 conferring resistance to colistin in CRE strains fur-
ther complicates therapeutic options [15], leaving only a limited num-
ber of drugs for the treatment of infections. Recently, Li et al., reported
the rapid increase of NDM and KPC as well as the emergence of mcr-1
in oneof the largest hospitals inHenan province [16]. Usually, CRE infec-
tions occur in hospitalized patients, nursing homes, and other
healthcare settings. Historically, CREwas usually thought to be acquired
within hospital institutions; however, recently, several studies have
suggested that CRE infections may be attributable to CRE colonized in
the normal ﬂora from healthy people [17]. Previous study also indicated
that there is an increased risk of CRE infection and mortality in patients
with CRE colonization at the time of intensive care unit (ICU) admission
[18]. However, the prevalence of CRE in the normal ﬂora of healthy peo-
ple has been poorly studied, and the potential risk of carriage of CRE in
the healthy population may have been underestimated.
Enterobacteriaceae, especially Escherichia coli, are the common and
normal ﬂora in healthy people, but are opportunistic pathogens and
can cause a variety of nosocomial infections. Our recent study showed
that high incidence of CRE was found in food animals, which may be
transmitted to humans through the food chain, resulting in thecolonization of CRE in healthy people [14]. The carriage of CRE might
not only pose a potential risk for healthy people, but also contribute to
the dissemination of these microorganisms in hospital settings. There-
fore, to better understand the current epidemiological trends and char-
acteristics of CRE in healthy people, we investigated the prevalence of
carbapenem-resistant E. coli (CREC) isolates collected from healthy vol-
unteers in 19 provinces across China. We also characterized the main
mechanism(s) conferring carbapenem resistance aswell as investigated
the emergence of mcr-1 in CREC.
2. Materials and Methods
2.1. Study Design
The aim of this study is to investigate the carriage of CREC, especially
the mcr-1 carrying CREC, in healthy people. We performed a cross-
sectional multi-center study from September 2016 to December 2016.
Stool specimens were collected from healthy people who received the
regular physical examinees in 52 general hospitals located in 19 prov-
inces including Beijing, Fujian, Guangdong, Guangxi, Guizhou, Hainan,
Heilongjiang, Henan, Hubei, Hunan, Inner Mongolia, Jilin, Jiangxi,
Ningxia, Shandong, Shanxi, Shaanxi, Tibet and Zhejiang, which
accounted for a population of 844.5 million (~60%) in China. All the vol-
unteers have been inquired about the medical history and antibiotic
prescription. Only volunteers, who have not been hospitalized and
taken any antibiotic in the last three months, will be selected for the
screening in this study. At least 50 samples were collected from each
province. In China, CRE screening is not a mandatory procedure in the
clinical medicine, but it is required if the patient will be administrated
into the ICU, and the screening guide is following the procedure issued
by the United States CDC.
Enrichment culture supplemented with 0.3 μg/ml meropenem was
used to isolate the CREC. Brieﬂy, about one-gram stool was inoculated
into 5 ml of buffered peptone water in a 10 ml tube and incubated at
37 °C overnight. A 10 μl aliquot of the Enterobacteriaceae Enrichment
broth was then spread onto a SS (Salmonella Shigella) agar plate sup-
plemented with 0.3 μg/ml meropenem and incubated at 37 °C over-
night. The pure colonies of E. coli were selected based on their color
and morphology, and the isolates were identiﬁed using matrix-
assisted laser desorption ionization/time of ﬂight mass spectrometry
(MALDI-TOF MS) (Bruker Daltonik GmbH, Bremen, Germany).
Ethical approval was given by The Second Afﬁliated Hospital of
Zhejiang University. Individual consent forms were translated into
Mandarin and consent was obtained for all healthy volunteers before
sampling.
2.2. Gene Screening and Whole Genome Sequencing
First, the presence of carbapenem-resistant genes (blaNDM, blaKPC,
blaIMP, blaVIM, blaOXA-48) and colistin-resistant gene (mcr-1) were
screened using PCR, and then the positive products were validated
with Sanger sequencing. All positive isolates were subjected to the
whole genome sequencing. Genomic DNA of isolate was extracted
using the Wizard Genomic DNA Puriﬁcation Kit (Promega, Beijing,
China), following the manufacturer's instructions. Indexed Illumina se-
quencing libraries were prepared using TruSeq DNA PCR-Free Sample
Preparation Kit (Illumina Inc., San Diego, CA) following the standard
protocol and sequenced on the Illumina HiSeq 2500 platform
(Annoroad Biotec Co.) according to the manufacturer's protocols. The
whole genome sequencing data was analyzed using multiple programs
including SPAdes (whole genome sequence assembly), SRST2 (antibi-
otic resistance gene andMLST analysis), BRIG (BLAST ring comparison),
Harvest and iTOL (phylogenetic tree analysis) as previously described
[14]. After the whole genome sequencing, gap ﬁling was conducted to
complete the NDM-5 carrying plasmid using PCR and Sanger
sequencing.
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Theminimum inhibitory concentrations (MICs) for the CREC isolates
against a panel of antibiotics were determined using broth micro-
dilution method according to the Clinical and Laboratory Standards In-
stitute (CLSI) guidelines. The results of antimicrobial susceptibility for
carbapenems (imipenem, meropenem), cephems (cefepime, ceftazi-
dime, cefotaxime, cefazolin, cefuroxime), piperacillin, β-lactam/β-
lactamase combination (piperacillin-tazobactam, ampicillin-
sulbactam, ticarcillin-clavulanate, cefoperazone-sulbactam (2:1),
ceftazidime-clavulanate, cefotaxime-clavulanate), aminoglycosides
(gentamicin, amikacin), ﬂuoroquinolones (ciproﬂoxacin, levoﬂoxacin),
trimethoprim-sulfamethoxazole, minocycline, aztreonam, chloram-
phenicol, fosfomycin, and nitrofurantoin were interpreted according
to CLSI guidelines, while the resistance for colistin and tigecycline was
interpreted according to the EuropeanCommittee onAntimicrobial Sus-
ceptibility Testing (EUCAST).2.4. Molecular Typing
All the blaNDM–positive E. coli were subjected to XbaI-digested
pulsed-ﬁeld gel electrophoresis (PFGE) typing. Salmonella enterica sero-
type Braenderup H9812 was used as a size marker. A dendrogram was
generated from the homology matrix with a coefﬁcient of 0.5% using
the unweighted pair-group method using arithmetic averages
(“UPGMA”) to describe the relationships among PFGE proﬁles. Isolates
were considered to belong to the same PFGE group if their Dice similar-
ity index was ≥85%.2.5. Statistical Analysis
The prevalence of CREC in this study are reported as a pooled
prevalence estimate with a 95% conﬁdence interval to represent resis-
tance from 2015 to 2016 and the analysis methodwas described as pre-
vious [19]. Brieﬂy, random effects meta-analysis was conducted for
individual data of province-speciﬁc prevalence to establish a properly
combined prevalence estimate for the national estimate by considering
between-province variation. All the statistical analysis was performed
in R version 3.3.1. Pooled prevalence was estimated using metafor
package.Table 1
Overview of sampling size and CREC in different provinces.
Sampling
provinces
NO. of
samples
NO. of
CREC
Positive rate of CREC (%; 95%
CI)
NO. of ND
CREC
Guizhou 50 4 8.0 (3.15–18.84) 1
Heilongjiang 50 3 6.0 (2.06–16.22) 0
Henan 56 3 5.36 (1.84–14.61) 1
Hunan 54 2 3.7 (1.02–12.54) 1
Beijing 418 13 3.11 (1.83–5.25) 4
Shandong 165 5 3.03 (1.30–6.90) 2
Fujian 100 3 3.0 (1.02–8.45) 0
Inner Mongoria 135 4 2.96 (1.16–7.37) 0
Tibet 108 3 2.78 (0.95–7.85) 2
Hainan 237 6 2.53 (1.17–5.41) 3
Shaanxi 132 3 2.27 (0.78–6.47) 1
Zhejiang 1551 35 2.26 (1.63–3.12) 19
Jilin 100 2 2.0 (0.55–7.00) 0
Guangxi 204 4 1.96 (0.77–4.93) 4
Ningxia 140 2 1.43 (0.39–5.06) 2
Guangdong 57 0 0.0 (0.0–0.0) 0
Hubei 52 0 0.0 (0.0–0.0) 0
Jiangxi 106 0 0.0 (0.0–0.0) 0
Shanxi 144 0 0.0 (0.0–0.0) 0
Total 3859 92 2.38 (1.95–2.91) 403. Results
3.1. Overview of the CREC
A total of 3859 non-duplicated stool specimens were collected from
healthy volunteers in 19 provinces during September 2016 to December
2016. The prevalence of CREC recovered from different sampling loca-
tions, 15 out of the 19 Provinces and Municipalities yielded CREC iso-
lates, except Guangdong, Hubei, Jiangxi and Shanxi (Table 1, Fig. 1A).
The age and gender information of the volunteers was also showed in
Fig. 1B and C, and the majority of the volunteers was between 25 and
44, accounting for about 60% of the population. The age and gender dis-
tribution was very similar in the CRE positive cases (age 38.16 ± 13.45,
Female 48.84% vs Male 51.16%) and the study population (age 37.51 ±
11.98, Female 45.48% vs Male 54.52%). Of 3859 isolates, a total of 92
(2.38%, 95% CI, 1.95%–2.91%) non-duplicated CREC isolates were ob-
tained (Table 1). We detected blaNDM, but not other carbapenem-
resistant genes, in 43 out of 92 isolates. From the 43 blaNDM genes, 40
(93.0%; 95% CI, 81.4%–97.6%) were blaNDM-5, and 3 (7.0%; 95% CI, 2.4%–
18.6%) blaNDM-1. In addition, the co-existence ofmcr-1 and blaNDM was
detected in 14 CREC. Interestingly, all blaNDM in the mcr-1 carrying
E. coli belong to blaNDM-5. These E. coli isolates with both NDM-5 and
MCR-1 were detected in six provinces (Table 1, Fig. 1). Approximately
40.2% of the total sampleswere fromZhejiang province,whichwere ob-
tained fromall 11 prefectural-level cities in Zhejiang province. The prev-
alence of CREC in Zhejiang is 2.26% (35 of 1551, 95% CI, 1.63–3.12%),
which is similar to the average level nationwide (2.38%; 95% CI,
1.95–2.91%). The E. coli isolates carrying both NDM-5 and MCR-1 were
detected in 5/11 cities (Table 2, Fig. 1).
3.2. Characterization of CREC
All NDM-producing E. coliwere resistant to almost all β-lactams. The
percentage of isolates susceptible to amikacin, colistin, tigecycline, and
nitrofurantoin were 76.7%, 72.1%, 88.4%, and 83.7%, respectively
(Table 3). All 14 MCR-1 and NDM-5 producing CREC exhibited resis-
tance to all β-lactams, but remained susceptible to amikacin (92.9%),
tigecycline (85.7%), and nitrofurantoin (92.9%) (Table 4). Moreover,
PFGE analysis on the 43 blaNDM–positive E. coli isolates indicated that
42/43 PFGE patternswere distinctly different using 85% genetic similar-
ity as cut-off, suggesting non-clonal dissemination is responsible for
their transmission across China (Fig. 2).M-5-producing NO. of NDM-1-producing
CREC
NO. of mcr-1 and blaNDM positive
CREC
0 0
0 0
0 1
0 0
1 1
1 1
0 0
0 0
0 1
0 2
0 0
1 8
0 0
0 0
0 0
0 0
0 0
0 0
0 0
3 14
Fig. 1. Summary of geography information. A) Positive regions forNDMand/orMCR carrying E. coli in China. The green and red indicated the presence of NDM-1 andNDM-5positive E. coli,
while the star indicates the presence of MCR-1 positive E. coli. The numbers of isolates are indicated in the brackets. B) The age distribution of the total sample population and
Carbapenemase Producing E. coli (CPE) positive case. C) The gender distribution of the total sample population and CPE positive.
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To further understand the genetic background of CREC and its role in
the dissemination of blaNDM andmcr-1, whole genome sequencing was
conducted to reveal plasmid and core genome information. The draftTable 2
Overview of sampling size and CREC in different cities in Zhejiang province.
Sampling
provinces
NO. of
samples
NO. of
CREC
Positive rate of CREC
(%; 95% CI)
NO. o
CREC
Lishui 98 6 6.12 (2.84–12.72) 5
Ningbo 144 5 3.47 (1.49–7.87) 4
Wenzhou 259 9 3.47 (1.84–6.47) 3
Shaoxing 83 2 2.41 (0.66–8.37) 1
Huzhou and Jiaxing 218 4 1.83 (0.72–4.62) 3
Taizhou 205 2 0.98 (0.27–3.49) 1
Hangzhou 377 7 1.86 (0.90–3.78) 2
Quzhou 66 0 0.0 0
Jinhua 101 0 0.0 0
total 1551 35 2.26 (1.63–3.12) 19whole genome sequence of 14mcr-1 positive E. coli (MCRPEC) isolated
showed that NDM-5 was located on contigs with lengths ranging from
41 to 46 kb in all NDM-5 carrying CREC, which was further conﬁrmed
by S1-PFGE (~46 kb) (data not shown). The complete sequence of the
blaNDM-5 carrying plasmid (designated pNDM5-ZJ628R,NCBI Accessionf NDM-5-producing NO. of NDM-1-producing
CREC
NO. of mcr-1 and blaNDM
positive CREC
0 4
0 0
1 1
0 0
0 2
0 0
0 1
0 0
0 0
1 8
Table 3
Antimicrobial susceptibility proﬁles of 43 clinical NDM-producing E. coli strains.
Drug class Antimicrobial agents MIC50
μg/ml
MIC90
μg/ml
Range
μg/ml
%R %I %S
Aminoglycoside Gentamicin 32 N32 ≤2–N32 69.8 2.3 27.9
Amikacin ≤8 N128 ≤8–N128 23.3 0.0 76.7
β-lactams and β-lactamase Inhibitor Piperacillin-tazobactam 256/4 N256/4 ≤8/4–N256/4 67.4 27.9 4.7
Ampicillin-sulbactam N64/32 N64/32 ≤4/2–N64/32 97.7 0.0 2.3
Ticarcillin-clavulanate 128/64 128/64 ≤8/4–128/64 95.3 0.0 4.7
Cefoperazone-sulbactam (2:1) N128/64 N128/64 64/32–N128/64 100.0 0.0 0.0
Carbapenem Imipenem N16 N16 8–N16 100.0 0.0 0.0
Meropenem N16 N16 8–N16 100.0 0.0 0.0
Cephalosporin Cefepime N32 N32 2–N32 90.7 7.0 2.3
Ceftazidime N32 N32 32–N32 100.0 0.0 0.0
Cefotaxime N32 N32 32–N32 100.0 0.0 0.0
Cefazolin N32 N32 32–N32 100.0 0.0 0.0
Cefuroxim N64 N64 64–N64 100.0 0.0 0.0
Fluoroquinolone Ciproﬂoxacin 8 N8 ≤0.25–N8 67.4 4.7 27.9
Levoﬂoxacin 16 N16 ≤0.5–N16 58.1 7.0 34.9
Sulfonamide and Trimethoprim Antibiotic Combinations Trimethoprim-sulfamethoxazole 8/152 8/152 ≤1/19–8/152 95.3 0.0 4.7
Fosfomycin 16 N512 ≤4–N512 39.5 2.3 58.1
Tetracycline Minocycline 8 16 ≤2–16 46.5 20.9 32.6
Tigecycline 0.5 2 ≤0.25–4 2.3 9.3 88.4
Others Aztreonam 4 64 ≤2–64 41.9 4.7 53.5
Chloramphenicol 32 32 ≤8–32 74.4 2.3 23.3
Colistin ≤1 4 ≤1–N16 27.9 0.0 72.1
Nitrofurantoin ≤32 64 ≤32–128 9.3 7.0 83.7
Piperacillin N256 N256 ≤8–N256 97.7 0.0 2.3
S, susceptible; I, intermediate resistant; R, resistant; MIC90 andMIC50 valueswere deﬁned as the lowest concentration of the antibiotic at which 90% and 50% of the isolates were inhibited,
respectively.
Table 4
MICs of 30 antimicrobial agents for 14 E. coli strains co-harboringmcr-1 and blaNDM-5.a
NO. of samples Province MIC (μg/ml)
IPN MPN FEP CAZ CTX CZ CXM PIP PIT AMS TCA SCF(2:1) CAC CTC
E218-2 Zhejiang 8 N16 N32 N32 N32 N32 N64 256 64/4 N64/32 128/64 128/64 N128/64 128/64
E628-1 Zhejiang 16 N16 N32 N32 N32 N32 N64 N256 128/4 N64/32 128/64 N128/64 N128/64 N128/64
E1164 Zhejiang N16 N16 N32 N32 N32 N32 N64 256 32/4 N64/32 128/64 N128/64 N128/64 N128/64
E1167 Zhejiang N16 N16 N32 N32 N32 N32 N64 N256 N256/4 N64/32 128/64 N128/64 128/64 N128/64
E1189 Zhejiang 8 N16 N32 N32 N32 N32 N64 N256 32/4 N64/32 128/64 128/64 N128/64 N128/64
E1230 Zhejiang 16 N16 N32 N32 N32 N32 N64 256 32/4 N64/32 128/64 N128/64 128/64 N128/64
E1462 Zhejiang 16 16 32 32 32 32 64 256 256/4 64/32 128/64 128/64 128/64 128/64
E1463 Zhejiang 16 N16 N32 N32 N32 N32 N64 N256 256/4 N64/32 128/64 N128/64 N128/64 N128/64
E774-1 Tibet N16 N16 N32 N32 N32 N32 N64 N256 128/4 N64/32 128/64 N128/64 N128/64 N128/64
E1908 Henan 16 16 N32 N32 N32 N32 N64 N256 16/4 N64/32 128/64 64/32 ≤1/0.5 ≤1/0.5
E2244 Beijing 16 N16 N32 N32 N32 N32 N64 N256 64/4 N64/32 ≤8/4 N128/64 N128/64 N128/64
E2498 Hainan N16 N16 N32 N32 N32 N32 N64 N256 128/4 N64/32 128/64 N128/64 N128/64 N128/64
E2525-1-2 Hainan N16 N16 N32 N32 N32 N32 N64 N256 N256/4 N64/32 128/64 N128/64 N128/64 N128/64
E3647-2 Shandong N16 N16 N32 N32 N32 N32 N64 N256 256/4 N64/32 128/64 N128/64 128/64 N128/64
NO. of samples Province MIC (μg/ml)
GM AN CIP LVF SXT MNO AZT C FOS FT TGC PE
E218-2 Zhejiang 32 ≤8 8 8 8/152 4 ≤2 32 512 ≤32 0.5 4
E628-1 Zhejiang N32 ≤8 N8 8 8/152 16 ≤2 32 512 ≤32 1 8
E1164 Zhejiang N32 ≤8 8 8 8/152 4 ≤2 32 N512 ≤32 ≤0.25 4
E1167 Zhejiang N32 N128 N8 16 8/152 16 16 32 ≤4 ≤32 ≤0.25 4
E1189 Zhejiang N32 ≤8 ≤0.25 ≤0.5 8/152 8 32 32 N512 ≤32 ≤0.25 ≤1
E1230 Zhejiang 16 ≤8 2 2 8/152 ≤2 ≤2 32 512 ≤32 ≤0.25 4
E1462 Zhejiang 4 ≤8 8 16 8/152 16 ≤2 32 16 128 1 4
E1463 Zhejiang ≤2 ≤8 N8 N16 8/152 16 4 32 ≤4 ≤32 4 ≤1
E774-1 Tibet N32 16 8 N16 8/152 16 ≤2 ≤8 128 ≤32 2 4
E1908 Henan ≤2 ≤8 4 4 8/152 4 ≤2 32 ≤4 ≤32 ≤0.25 2
E2244 Beijing N32 ≤8 N8 N16 8/152 16 64 32 N512 ≤32 0.5 2
E2498 Hainan 32 ≤8 ≤0.25 ≤0.5 8/152 4 ≤2 32 N512 ≤32 ≤0.25 4
E2525-1-2 Hainan ≤2 ≤8 ≤0.25 ≤0.5 8/152 16 16 32 ≤4 ≤32 1 4
E3647-2 Shandong N32 ≤8 N8 8 8/152 16 64 32 N512 ≤32 0.5 2
IPN, Imipenem; MPN, Meropenem; FEP, Cefepime; CAZ, Ceftazidime; CTX, Cefotaxime; CZ, Cefazolin; CXM, Cefuroxim; PIP, Piperacillin; PIT, Piperacillin-tazobactam; AMS, Ampicillin-
sulbactam; TCA, Ticarcillin-clavulanate; SCF (2:1), Cefoperazone-sulbactam (2:1); CAC, Ceftazidime-clavulanate; CTC, Cefotaxime-clavulanate; GM, Gentamicin; AN, Amikacin; CIP, Cip-
roﬂoxacin; LVF, Levoﬂoxacin; SXT, Trimethoprim-sulfamethoxazole; MNO, Minocycline; AZT, Aztreonam; C, Chloramphenicol; FOS, Fosfomycin; FT, Nitrofurantoin; TGC, Tigecycline;
PE, colistin.
a The bold values indicated these strains were susceptible to the drugs according to EUCAST and CLSI standards.
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Fig. 2. PFGE analysis of carbapenem-resistant E. coli, XbaI was used for digestion of the genomic DNA.
16 Z. Shen et al. / EClinicalMedicine 6 (2018) 11–20No.MH500845) from isolate E628-1was acquired through gapﬁlling by
sequencing PCR amplicons. pNDM5-ZJ628R belongs to the IncX3 family,
which was 46,161-bp in length with a G/C content of 46.6%. This plas-
mid contains 60 putative open reading frames (ORFs) and the gene
components of the plasmid are show in Fig. 3A. Of the 40 NDM-5 carry-
ing CREC, 23 plasmid sequences were closed for the full length of the
plasmid (~46 kb) and selected for comparison with ﬁve other IncX3
plasmids carrying blaNDM-5 identiﬁed from animal farms and showed
over 99% identity (Fig. 3A). The draft sequences of the other NDM-5 car-
rying plasmids showed all were highly similar to pNDM5-ZJ628R.
S1-PFGE analysis showed mcr-1 was mostly located on plasmids
with lengths of 240–330 kb, and two were located on the chromosome
(Fig. 5).Whole genome sequencing conﬁrmed that the plasmid Inc. typeis IncHI2, which was similar to plasmid pHNSHP45-2 [20]. Comparison
ofmcr-1 carrying plasmid sequences are shown in Fig. 3B. The sequenc-
ing of nine isolates carryingmcr-1 shares over 90% identity and 90% cov-
erage with plasmid pHNSHP45-2.
Core genome analysis of CREC and MCRPEC revealed 6 distinct line-
ages (Fig. 4). A total of 165,857 core SNPs were used to analyze the re-
lationship among these isolates, and most isolates identiﬁed from the
same region or adjacent region could be found in the same or closing
lineage. We found these strains can be allocated across 32 ST clades,
and none of these ST clades was dominant, afﬁrming our PFGE analysis.
Interestingly, the average number of antibiotic resistance genes are 18.7
± 4.6 in themcr-1-negative CREC, and 24.3 ± 3.7 in themcr-1-positive
CREC, indicating thatmcr-1-carrying CREC are likely to carrymore ARGs
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Fig. 3. BLAST ring comparison of NDM-5 andMCR-1 plasmids. A) The comparison of NDM-5 carrying plasmid sequences in CREC isolates. Each color represents a NDM-5 carrying plasmid.
The internal ring is the reference sequence of NDM-5 carrying plasmid pNDM-ZJ628R, and the outside rings are other 23 plasmids from this study and 5 plasmids of animal origin, which
are highly similar to pNDM-ZJ628R. B) The comparison ofmcr-1 carrying plasmid sequences inmcr-1 positive CREC isolates. Each color represents amcr-1 carrying plasmid. The internal
ring is the reference sequence ofmcr-1 carrying plasmid pHNSHP45-2, and the outside rings are other 14 plasmids from this study, which are similar to pNDM-ZJ628R.
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people (P-value b 0.05).
4. Discussions
Since the ﬁrst discovery of NDM-1 in 2009, over 20 NDM variants
have now been reported. A nationwide Chinese survey demonstratedthat the acquisition of two carbapenemases, KPC and NDM,was respon-
sible for phenotypic resistance in 90% of the CRE strains tested (58% and
32%, respectively) [2]. In E. coli, the proportion of NDMwas higher than
that of KPC [2]. So far, majority of the epidemiology studies of CRE have
focused on clinical data, as it was deemed that healthy individuals were
usually not affected by the carriage of CRE. Hitherto, there have only few
studies about the prevalence of CRE in the normal ﬂora of a healthy
Fig. 4. The phylogenetic relationship of CREC andmcr-1 positive CREC, and their other antibiotic resistance genes. The left phylogenetic tree were constructed using the core SNPs with ST
types. The color squares represent the antibiotic resistance genes sorted by the class of antibiotics.
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ology study of the carriage of CRE in the healthy Chinese population.
To date, over 20 NDMhas been discovered, and blaNDM-1 appears to
be overwhelmingly dominated in the clinical sector. Amit Ranjan et al.Fig. 5. S1-PFGE analysis ofmcr-1positive CREC. BandsM:H9812, 1:E218-2, 2:E628-1, 3:E774-1,
E2525-1, 14:E3647-2, M:H9812.reported that the majority of MBL producers were NDM-1 (69%)
followed subsequently by NDM-5 (19%) in extra-intestinal pathogenic
E. coli strains [22]. Another study showed the similar ﬁnding in China
from 2013 to 2015, 80% was NDM-1, and 17.8% was NDM-5 [23].4:E1164, 5:E1167, 6:E1189, 7:E1230, 8:E1462, 9:E1463, 10:E1980, 11:E2244, 12:E2498, 13:
19Z. Shen et al. / EClinicalMedicine 6 (2018) 11–20Surprisingly, in our study, the number of NDM-5 producing E. coli iso-
lated in the gut ﬂora (40 strains) was much higher than that of NDM-
1 producing E. coli (3 strains), suggest the prevalence of NDM has
been shifting from NDM-1 to NDM-5 in the community of China, but
this shift has not been observed in India and other countries yet.
Since theﬁrst discovery of blaNDM-5 in China, blaNDM-5 has been iden-
tiﬁed in a variety of Enterobacteriaceae, and the Inc. type primarily car-
rying blaNDM-5 is IncX3. In this study, pNDM5-ZJ628R was identiﬁed as
an IncX3 plasmid, with a typical backbone structure for this plasmid
type, including regions involved in replication, partitioning, plasmid
maintenance, transcriptional activation, and conjugation/type IV secre-
tion [24,25], which is very similar to the plasmids carrying blaNDM-5 in
the CREC and MCRPEC (Fig. 3A and B).
The comparative analysis of 23 blaNDM-5 carrying plasmids (the
contigs close to the full length of plasmid) revealed that these plasmids
possessed very high similarity to the closed sequenced plasmid
pNDM5-ZJ628R. BLAST homology analysis showed that pNDM5-
ZJ628R had 100% identity and 100% query coverage with pP855-
NDM5 (accession number: MF547508) and pNDM5_IncX3 (accession
number: KU761328), a 46,161-bp IncX3 plasmid isolated from E. coli
(accession number: P855MEM) of pig origin and Klebsiella pneumoniae
(SZ204) of human origin [26]. Recently, a novel blaNDM-17 was discov-
ered in E. coli from poultry in China. This blaNDM-17 carrying plasmid
also belongs to IncX3 (GenBank accession no. KX833071), sharing 99%
identity (46,142/46,161 bp) and 100% coverage with NDM5_IncX3
(KU761328), a 46,161-bp IncX3 plasmid isolated from Klebsiella
pneumoniae (SZ204) [27]. In comparison with NDM-5, NDM-17 has a
single E170K substitution and showed increased resistance to carbapen-
ems, which may suggested blaNDM-5 IncX3 plasmid could be a pivotal
branch for further evolution of NDM carbapenemases. The IncX3 plas-
mid carrying blaNDM-1 pNDM-HN380 (54,035 bp) [ 22] was reported
in Hong Kong in 2012 was also very similar to pNDM5-ZJ628R
(46,161 bp) apart from an 8 kb region, which may suggest this plasmid
could be the origin of the IncX3 plasmid. Although IncX3 plasmids are
considered low-prevalence, narrow-host-range plasmids of Enterobac-
teriaceae [12], our MLST analysis showed IncX3 plasmids have a wide
host adaption capability in E. coli. These plasmids may have served as
a common vehicle in disseminating blaNDM in E. coli among human, an-
imal, and environment sectors, and might be responsible for the rapid
spread of NDM-carrying isolates [13].
The overwhelming prevalence of blaNDM-5 in E. coli in the healthy
population seem to be identical with the trend of blaNDM-5 in E. coli
from the Chinese poultry production chain. A recent study reported
blaNDM-5 accounted for 52.2% of all CRE isolates (84/161); not only in
poultry farms, but also slaughterhouses, supermarkets, and poultry
farm workers [14], which suggests a dynamic transition for blaNDM
among human, animal and the environment.
It is worth noting that almost one third of the total carbapenemase
producing E. coli isolates (14 out of 43) carry mcr-1, suggesting an
emerging co-existence of blaNDM and mcr-1 in Enterobacteriaceae in
human normal ﬂora from healthy volunteers. The co-existence of
blaNDM-5 andmcr-1 has been occasionally observed at a low prevalence
in individual clinical samples [28–30], and to the best of our knowledge,
this is the ﬁrst report of the co-existence of blaNDM-5 and mcr-1 in the
normal ﬂora of humans. Interestingly, 23% of CRE isolates of animal or-
igin from Shandong province showed a high co-existence of blaNDM and
mcr-1, which is consistent with the ﬁndings in this study [14]. Although
whole genome sequencing could not retrieve the complete sequence of
mcr-1 carrying plasmids, the comparative analysis between whole ge-
nome draft sequences and two common mcr-1 carrying plasmids
(pHNSHP45 and pHNSHP45-2) showed the majority of mcr-1 carrying
contigs share high similarity to plasmid pHNSHP45-2. Moreover, MLST
analysis also indicates the wide host adaptability of pHNSHP45-2 like
plasmids in E. coli isolates from different regions in China.
The relative small number of samples is one of the limitations for this
study, comparing with the population size in China, as this study is justan observation study for understanding the prevalence of CREC in the
healthy people. Although the CRE positive case number is small, but it
suggests the prevalence of CREC in the healthy people does exist, and
the colonization of CREC in the healthy people may contribute to the
later infection in the hospital. Now, according to the CHINET Surveil-
lance Program, the prevalence of CREC in the hospital in about 2.0%
based on 36,375 EREC isolates [31], which is similar to the prevalence
of CREC in the healthy people. Another limitation is the limited informa-
tion of geography from the volunteers, such as antibiotic consumption,
poultry consumption, etc., which makes it difﬁcult to identify the risks
related to the colonization of CREC in the healthy people.
This is the ﬁrst comprehensive study to reveal the emerging co-
existence of blaNDM-5 andmcr-1 in the normal gut ﬂoral of healthy indi-
viduals. Our ﬁndings further suggest that the dissemination of blaNDM-5
may be augmented by the presence IncX3-type plasmids. Due to the
high prevalence of CRE in the healthy human population, it is urgent
to implement a screening procedure to monitor the presence of CRE
for patients admitted onto hospital high dependency units e.g. oncology
to prevent the dissemination of CRE in high-risk patients.
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